Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: musculoskeletal disease

Lost and found

Understanding the Role of Uric Acid in Gout

Ruth Jessen Hickman, MD  |  September 6, 2022

From the first substantial argument in the 19th century that uric acid played a role in gout, it took about 100 years for the medical community to accept its role in triggering acute inflammatory gout attacks. Two papers, both published in 1962, helped demonstrate the link between uric acid and acute gout attacks, quickly opening…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:GoutGout Resource CenterLost & FoundUric acid

Rheumatologists Can & Should Help Combat Medical Misinformation

Kenneth G. Saag, MD, MSc  |  August 14, 2022

The Surgeon General has identified medical misinformation as a major public health threat, and many professional societies, including the American Medical Association, have called for action to combat it,” writes Richard J. Baron, MD, American Board of Internal Medicine (ABIM) chief executive officer, and Yul D. Ejnes, MD, ABIM’s board chair, in The New England…

Filed under:President's PerspectiveProfessional Topics Tagged with:misinformationtrust

Difficult-to-Treat Lupus: When & How to Use New Therapies

Samantha C. Shapiro, MD  |  July 21, 2022

Clinicians have numerous treatment options for SLE; in a EULAR 2022 session, some of the newer therapies were reviewed.

Filed under:ConditionsEULAR/OtherMeeting ReportsSystemic Lupus Erythematosus Tagged with:belimumabEULARHCQHydroxychloroquine (HCQ)rituximabSLEsystemic lupus erythematosus (SLE)

Baricitinib Promising for Juvenile Idiopathic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  July 19, 2022

In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.

Filed under:ConditionsDrug UpdatesEULAR/OtherMeeting ReportsPediatric Conditions Tagged with:baricitinibEULARflareJIAjuvenile idiopathic arthritis (JIA)PediatricPediatric Rheumatology

Predicting the Future: Prognostication in Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  July 19, 2022

A EULAR 2022 abstract session looked at several studies that seek to increase understanding of RA pathogenesis & identify patients at risk for disease progression.

Filed under:ConditionsEULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:anti-advanced glycated end-products (anti-AGE) antibodiesanti-malondialdehyde-acetaldehyde (anti-MAA) antibodiesEULARRheumatoid Arthritis (RA)synovialTenosynovitis

Teaching Junior Learners in Rheumatology

Ian D. Cooley, MD, & Eli M. Miloslavsky, MD  |  July 13, 2022

Teaching junior learners, such as medical students and residents, is increasingly important in rheumatology. Given the antici­pated shortage of rheumatologists, attracting more trainees to our field and enhancing knowledge of the rheumatic diseases among physicians in other fields are critical to meeting the needs of our patients.1,2 In addition, clinical reasoning is a vital skill…

Filed under:Education & Training Tagged with:apprenticePreceptorshipteaching

Case Report: Dermato-Neuro Syndrome Recurrence after a Viral Infection

Case Report: Dermato-Neuro Syndrome Recurrence after a Viral Infection

Fazila Aseem, MD, MPH, Alexander D. Jeffs, MD, Enid Y. Sun, MD, MPH, Randaline R. Barnett, MD, Courtney Blodgett, AG-ACNP, Winnie Lau, MD, Casey Olm-Shipman, MD, MS, Matthew F. Sharrock, MD, Rhonda Cadena, MD, Yueh. Z. Lee, MD, PhD, Alfredo C. Rivadeneira, MD, & Clio A. Rubinos, MD, MS  |  July 13, 2022

Scleromyxedema is a primary cutaneous mucinosis characterized by a diffuse and generalized papular skin eruption of mucinous deposits throughout the upper dermis. In addition to dermatologic manifestations, scleromyxedema may involve the cardiopulmonary, gastrointestinal, renal and nervous systems. Dermato-neuro syndrome (DNS) is a rare, severe neurologic complication of scleromyxedema.1,2 The pathogenesis of DNS is unknown, but…

Filed under:ConditionsSystemic Sclerosis Tagged with:case reportCOVID-19Dermato-Neuro SyndromeFellowsScleromyxedema

The ACR Responds to Impact of the Dobbs v. Jackson Decision on Rheumatology Patients and Providers

Joseph Cantrell, JD, & Kenneth G. Saag, MD, MSc  |  July 13, 2022

The ACR and a new Access to Reproductive Health Care Task Force are working to ensure patients with rheumatic disease—particularly women—have access to the medications and treatments they need, including methotrexate, and that rheumatology providers are able to maintain trusting relationships with and advise their patients on all matters relevant to the management of their rheumatic diseases.

Filed under:American College of RheumatologyConditionsLegislation & Advocacy Tagged with:Access to careAccess to Reproductive Health Care Task ForceACR advocacyLegalMethotrexatereproductive health

Updates from the ACR’s Committee on Rheumatology Training & Workforce Issues

Jason Liebowitz, MD, FACR  |  June 17, 2022

The ACR’s Committee on Rheumatology Training & Workforce Issues helps young rheumatologists to become successful and find meaning in their work. Here is an update on the committee’s most recent accomplishments.

Filed under:Education & TrainingMeeting ReportsOther ACR meetings Tagged with:ACR Education Exchangeeducation and trainingonline educationTrainingWorkforce

PsA Trial Design Can Improve Patient Safety, Outcomes

Vanessa Caceres  |  June 15, 2022

For best safety and efficacy outcomes, trials in psoriatic arthritis should use active comparators and stricter remission criteria, with outcome measures that are important to patients.

Filed under:ConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR-FDA Summitclinical trialsPsoriatic Arthritisstudy design

  • « Previous Page
  • 1
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • …
  • 93
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences